

Reiki Nishimura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7489930/publications.pdf>

Version: 2024-02-01

49
papers

859
citations

516215

16
h-index

476904

29
g-index

52
all docs

52
docs citations

52
times ranked

1470
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. <i>Breast Cancer</i> , 2010, 17, 269-275.	1.3	111
2	The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 15584-15592.	0.8	101
3	Is triple negative a prognostic factor in breast cancer?. <i>Breast Cancer</i> , 2008, 15, 303-308.	1.3	96
4	Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 90-98.	5.1	84
5	Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study. <i>PLoS ONE</i> , 2015, 10, e0119565.	1.1	58
6	Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2019, 24, 274-287.	1.0	43
7	p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. <i>International Journal of Clinical Oncology</i> , 2006, 11, 426-433.	1.0	30
8	Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. <i>Breast Cancer</i> , 2008, 15, 57-64.	1.3	30
9	The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index. <i>Journal of Clinical Pathology</i> , 2016, 69, 255-259.	1.0	30
10	Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase III study. <i>Cancer Science</i> , 2018, 109, 803-813.	1.7	29
11	Microsatellite instability in Japanese female patients with triple-negative breast cancer. <i>Breast Cancer</i> , 2020, 27, 490-498.	1.3	28
12	BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0167016.	1.1	23
13	CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 558-566.	0.8	23
14	Elevated serum ca15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer. <i>Breast Cancer</i> , 2003, 10, 220-227.	1.3	21
15	Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors. <i>Oncology Letters</i> , 2019, 17, 616-622.	0.8	19
16	Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab. <i>Oncology</i> , 2017, 93, 51-61.	0.9	18
17	T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 569-577.	1.1	18
18	Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer. <i>Experimental and Therapeutic Medicine</i> , 2012, 3, 66-71.	0.8	13

#	ARTICLE	IF	CITATIONS
19	An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer. <i>Breast Cancer</i> , 2002, 9, 145-152.	1.3	10
20	Palbociclibâ€“etrozole as firstâ€“line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study. <i>Cancer Medicine</i> , 2020, 9, 4929-4940.	1.3	10
21	Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1217-1225.	2.9	8
22	Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 2331.	1.0	8
23	Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. <i>British Journal of Cancer</i> , 2020, 122, 1747-1753.	2.9	7
24	Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicinâ€“docetaxel neoadjuvant chemotherapy: a cohort study. <i>Breast Cancer</i> , 2009, 16, 42-48.	1.3	6
25	Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. <i>Breast Cancer</i> , 2020, 27, 631-641.	1.3	6
26	Investigation of factors related to periods to ipsilateral breast tumor recurrence after breast-conserving surgery and measures for preventing recurrence in early breast cancer. <i>Breast Cancer</i> , 2006, 13, 152-158.	1.3	5
27	Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 631-635.	1.1	4
28	The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs. <i>Breast Cancer</i> , 2020, 27, 973-981.	1.3	4
29	The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial. <i>Surgical Oncology</i> , 2021, 36, 51-55.	0.8	4
30	An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer. <i>Oncology Letters</i> , 2022, 24, .	0.8	4
31	Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial. <i>Anti-Cancer Drugs</i> , 2008, 19, 911-915.	0.7	2
32	Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1268-1274.	0.4	2
33	A randomized phase II trial evaluating <i>CYP2D6</i> genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1046-1046.	0.8	2
34	Biology and prognosis of HER2-negative breast cancer with low-ER and PgR-expressions.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12020-e12020.	0.8	1
35	Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free interval. <i>Anticancer Research</i> , 2004, 24, 2085-91.	0.5	1
36	A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study. <i>Clinical Breast Cancer</i> , 2021, 21, 450-457.	1.1	0

#	ARTICLE	IF	CITATIONS
37	Baseline neutrophil-to-lymphocyte ratio and absolute lymphocyte count in patients with HER2-negative breast cancer treated with eribulin may predict overall survival.. Journal of Clinical Oncology, 2021, 39, e13005-e13005.	0.8	0
38	Correlation between HER2 related biomarkers (HER2, p95HER2, HER3, PTEN and PIK3CA) and treatment outcome of lapatinib plus capecitabine in HER2-positive metastatic breast cancer refractory to trastuzumab.. Journal of Clinical Oncology, 2016, 34, e12085-e12085.	0.8	0
39	Overall survival of participants compared to non-participants in a randomized-controlled trial (SELECT BC): A prospective cohort study.. Journal of Clinical Oncology, 2016, 34, 2527-2527.	0.8	0
40	Efficacy and safety of everolimus for heavily pretreated patients with ER+/HER2- metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, e12041-e12041.	0.8	0
41	Biomarker analysis of S-1 in SELECT-BC: A randomized phase III study of taxane versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT-BC EURECA).. Journal of Clinical Oncology, 2016, 34, e23274-e23274.	0.8	0
42	Psychological Resistance to Receiving <I>BRCA2</I> Mutation-positive Resultsâ€™A Case Studyâ€™. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2018, 79, 1820-1824.	0.0	0
43	Evaluation of androgen receptor expression in pretreatment, posttreatment and recurrent breast cancer patients.. Journal of Clinical Oncology, 2018, 36, e12554-e12554.	0.8	0
44	Evaluation of androgen receptor expression in core needle biopsies and clinico-pathological factors in primary breast cancer.. Journal of Clinical Oncology, 2019, 37, e12023-e12023.	0.8	0
45	Evaluation of oral S-1 as a first-line chemotherapy for metastatic HER2-negative breast cancer: An analysis of two randomized phase III studies (SELECT BC-CONFIRM and SELECT BC).. Journal of Clinical Oncology, 2019, 37, 1083-1083.	0.8	0
46	Biological analysis of HER2 equivocal (2+) cases in primary breast cancer.. Journal of Clinical Oncology, 2020, 38, e12555-e12555.	0.8	0
47	Abstract P4-07-09: Triple negative breast cancer: An analysis of the subtypes and the effects of menopausal status on invasive breast cancer. Cancer Research, 2022, 82, P4-07-09-P4-07-09.	0.4	0
48	Abstract P4-07-12: An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer. Cancer Research, 2022, 82, P4-07-12-P4-07-12.	0.4	0
49	Longitudinal efficacy and safety of capecitabine and cyclophosphamide as early-line treatment in patients with metastatic breast cancer: A prospective cohort study by the Kyushu Breast Cancer Study Group, Japan.. Annals of Cancer Research and Therapy, 2022, 30, 38-44.	0.1	0